Answer
Oct 08, 2026 - 10:00 AM
Brukinsa is used for the treatment of certain blood cancers, including Chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) in combination with obinutuzumab, mantle cell lymphoma (MCL) after at least one prior therapy, Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL) that has relapsed or not responded to treatment. Having a targeted medication for these conditions offers more effective and personalized treatment options for patients facing these serious diseases.
